CSL Ltd. — Capital/Financing Update 2007

Feb 1, 2007

CSL Limited 45 Poplar Road Parkville Victoria 3052 Australia

T +613 9389 1911 F +613 9389 1434 www.csl.com.au

ASX Announcement

For immediate release

2 February 2007

CSL Secures Long Term Supply of Helixate from Bayer

CSL Limited announced today that it had concluded an agreement with Sanofi-Aventis that had facilitated an extension of the arrangements with Bayer for the supply of Helixate FS, CSL Behring's recombinant Factor VIII product. CSL advised that the previous agreement with Bayer on Helixate FS would have expired in 2009, with the new arrangement securing supply for a further eight years until the end of 2017. CSL reported that in the last financial year, Helixate FS generated revenues of US\$340 million.

CSL advised that it had agreed to pay Sanofi-Aventis the Contingent Payment of US\$250m¹ and the Deferred Payment of US\$65m² earlier than originally agreed when CSL acquired Aventis Behring in 2004. This agreement with Sanofi-Aventis has enabled CSL to independently negotiate with Bayer the sublicensing terms of certain intellectual property related to recombinant Factor VIII, to secure the long-term supply of Helixate FS and to facilitate the settlement of litigation against Bayer. CSL also noted that a number of other outstanding matters that had remained unresolved with Sanofi-Aventis stemming from the original 2004 acquisition of Aventis Behring had also now been resolved.

Dr McNamee commented that he was pleased that all parties had gained substantially from the outcome of complex negotiations, which had resulted in securing the long-term supply of CSL Behring's key lifesaving product Helixate FS for the benefit of the patient communities that the Company serves.

¹ CSL had made provision for this Contingent Payment at the time of its full year result announcement in August 2006. CSL had agreed at the time of the acquisition of Aventis Behring in March 2004 to pay US\$250m to Aventis (now Sanofi-Aventis) on 31 March 2008 if the volume weighted average price of CSL's shares for any 60 consecutive trading day period during the six months prior to the end of March 2008 exceeded A\$35.00.

² CSL had agreed at the time of the acquisition of Aventis Behring in March 2004 to pay Aventis (now Sanofi-Aventis) on 31 December 2007 the sum of US\$65m as a deferred payment.

For more information about CSL Limited, visit www.csl.com.au

Media Contact:

Australia and New Zealand Dr Rachel David Director of Public Affairs Phone: 0401 775 779 Email: rachel.david@csl.com.au

Investor Contact:

Mark Dehring Director of Investor Relations Phone: 61 3 9389 2818 Email: mark.dehring@csl.com.au